Gland Pharma's Q1 FY27 net profit grew 47% YoY to ₹317 crore, despite a 14% sequential decline. Revenue rose 20% YoY to ₹1,800 crore, driven by CDMO and B2B businesses, with strong contributions from the US and Europe markets.
Gland Pharma's Q1 FY27 net profit grew 47% YoY to ₹317 crore, despite a 14% sequential decline. Revenue rose 20% YoY to ₹1,800 crore, driven by CDMO and B2B businesses, with strong contributions from the US and Europe markets.
<iframe src="https://hindustansphere.com/embed/cluster/59270dece1991334de4e441127f614fe9871d14d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Gland Pharma Q1 Results: Net profit jumps 47% YoY to ₹317 crore; CDMO revenue rises 20%"></iframe>
